Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | G6PD | P11413 | 1/20 | 0.49 |
| ▸ | PYGB | P11216 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9612320 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL19738683 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL2621548 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL15215701 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL13879350 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL15621594 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL15061687 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL21847893 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL20745165 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR | |
| SCHEMBL16946217 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTLGALS8GAATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112367987-A | Active agents and methods for their use in treating metabolic disorders and non-alcoholic fatty liver disease | 旗舰创业创新五公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-9840530-B2 | Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-12-12 | — | — | US | disclosed |
| CN-105828612-A | Synergistic Pesticidal Compositions And Related Methods | 美国陶氏益农公司 | 2016-08-03 | — | — | CN | disclosed |
| US-20150337000-A1 | Mannose-Receptor Selective Lysinylated Cationic Amphiphiles and a Process for Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-11-26 | — | — | US | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337000-A1 | Mannose-Receptor Selective Lysinylated Cationic Amphiphiles and a Process for Preparation Thereof | M6PR, MRGPRX2, MRGPRX1 | L3MBTL1 2597/4885MAPT 4046/4885LGALS8 179/4885 |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | L3MBTL1 4511/4885MAPT 3186/4885LGALS8 295/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | L3MBTL1 4511/4885MAPT 3186/4885LGALS8 295/4885 |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | L3MBTL1 4511/4885MAPT 3186/4885LGALS8 295/4885 |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | L3MBTL1 4511/4885MAPT 3186/4885LGALS8 295/4885 |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | L3MBTL1 4511/4885MAPT 3186/4885LGALS8 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.